Table 1.
Peer-reviewed data from large phase III trials conducted in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
| Study, line (year) | N | Regimen (treatment arms A, B, C) | Response rate (%) | Median progression-free survival (months) | Median overall survival (months) |
|---|---|---|---|---|---|
| ECOG 5397 1st line (2005) [34] |
112/ | A: P + cetuximabb | 26e | 4.2 | 9.2 |
| 117 | B: P + placebo | 10 | 2.7 | 8.0 | |
| EXTREME 1st line (2008) [18] |
442/ | A: PF/CF + cetuximabb | 36e | 5.6e | 10.1e |
| 442a | B: PF/CF | 20 | 3.3 | 7.4 | |
| SPECTRUM 1st line (2013) [35] |
657/ | A: PF + panitumumabb | 36e | 5.8e | 11.1 |
| 657a | B: PF | 25 | 4.6 | 9.0 | |
| IMEX 2nd line (2009) [36] |
456/ | A: Gefitinib (250 mg)b | 2.7 | ND | 5.6 |
| 486a | B: Gefitinib (500 mg)b | 7.6 | ND | 6.0 | |
| C: MTX | 3.9 | ND | 6.7 | ||
| ZALUTE 2nd line (2011) [37] |
286/ | A: Zb + BSC | 6.3 | 2.3e | 6.7 |
| 286a | B: BSC (optional MTX) | 1.1 | 1.9 | 5.2 | |
| ECOG 1302 2nd line (2013) [38] |
177/ | A: D + gefitinibb | 12.5 | 3.5 (TTP) | 7.3 |
| 239a | B: D + placebo | 6.2 | 2.1 (TTP) | 6.0 | |
| LUX-Head&Neck1 2nd line (2015) [39] |
483/ | A: Afatinibc | 10.2 | 2.6e | 6.8 |
| 483a | B: MTX | 5.6 | 1.7 | 6.0 | |
| CheckMate-141 2nd line (2016) [23] |
361/ | A: Nivolumabd | 13.3e | 2.0 | 7.5e |
| 361a | B: MTX or D or cetuximabb | 5.8 | 2.3 | 5.1 |
N number of patients analysed for response/efficacy, P cisplatin, C carboplatin, F 5-fluorouracil, MTX methotrexate, Z zalutumumab, BSC best supportive care, D docetaxel, ND no data, TTP time to progression
aintention-to-treat population
bepidermal growth factor receptor inhibitor
cirreversible HER family receptor blocker
dprogrammed cell death protein-1 inhibitor
esignificant differences